References
- Howlader NNA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, et al (eds). SEER Cancer Statistics Review, 1975-2016. Bethesda, MD: National Cancer Institute; 2019.
- Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 2021;7(12):1824–32. doi:https://doi.org/10.1001/jamaoncol.2021.4932.
- Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640–9. doi:https://doi.org/10.1056/NEJMoa1916623.
- Desai A, Gyawali B. Fall in US cancer death rates: time to pop the champagne? EClinicalMedicine. 2020;19:100279. doi:https://doi.org/10.1016/j.eclinm.2020.100279.
- Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–40. doi:https://doi.org/10.1016/j.mayocp.2019.01.013.
- European Lung Cancer Congress 2022. Available from: https://www.esmo.org/meetings/past-meetings/european-lung-cancer-congress-2022.
- Choe G, Carr R, Molena D. New surgical approaches in the treatment of non-small cell lung cancer. Clin Chest Med. 2020;41(2):175–83. Jundoi:https://doi.org/10.1016/j.ccm.2020.02.007.
- Veiga Oliveira P, Cabral D, Antunes M, Torres C, Alvoeiro M, Rodrigues C, et al. Lung resection for non-small-cell lung cancer – a new risk score to predict major perioperative complications. Port J Card Thorac Vasc Surg. 2022;28(4):31–6.
- Xie D, Deschamps C, Shen RK, Deng B, Wampfler JA, Cassivi SD, et al. Bilobectomy versus lobectomy for non-small cell lung cancer: a comparative study of outcomes, long-term survival, and quality of life. Ann Thorac Surg. 2015;100(1):242–50. doi:https://doi.org/10.1016/j.athoracsur.2015.03.018.
- Li A, Canavan ME, Ermer T, Kaminski M, Maduka R, Zhan P, et al. 109MO respect the middle lobe: perioperative survival of bilobectomy compared to lobectomy and pneumonectomy. Ann Oncol. 2022;33:S82. doi:https://doi.org/10.1016/j.annonc.2022.02.136.
- Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. doi:https://doi.org/10.1016/j.jtho.2015.09.009.
- Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1–iv21. doi:https://doi.org/10.1093/annonc/mdx222.
- Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344–57. doi:https://doi.org/10.1016/S0140-6736(21)02098-5.
- Administration UFD. FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer 2021. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer.
- Felip E, Altorki NK, Zhou C, Vallieres E, Vynnychenko IO, Akopov A, et al. 80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study. Eur Soc Med Oncol Ann Oncol Elsevier. 2022;33:S71. doi:https://doi.org/10.1016/j.annonc.2022.02.090.
- Paz-Ares L, O'Brien MER, Mauer M, et al. VP3-2022: pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study. Ann Oncol. 2022;33(4):451–3.
- Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29. doi:https://doi.org/10.1056/NEJMoa1709937.
- Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares LG, et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: an update from the PACIFIC trial. JCO. 2021;39(15_suppl):8511. doi:https://doi.org/10.1200/JCO.2021.39.15_suppl.8511.
- Garassino MC, Mazieres J, Reck M, Chouaid C, Bischoff H, Reinmuth N, et al. 108MO safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6). Ann Oncol. 2022;33:S81–S82. doi:https://doi.org/10.1016/j.annonc.2022.02.135.
- Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022;23(2):209–219. doi:https://doi.org/10.1016/S1470-2045(21)00630-6.
- Markham A, Keam SJ. Camrelizumab: first global approval. Drugs. 2019;79(12):1355–1361. doi:https://doi.org/10.1007/s40265-019-01167-0.
- Zhou C, Ren S, Chen J, Xu X, Cheng Y, Chen G, et al. 96O Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): a randomized, double-blind, multicenter, phase III trial. J Thoracic Oncol. 2021;16(4):S748. doi:https://doi.org/10.1016/S1556-0864(21)01938-9.
- Zhou C, Cheng Y, Chen J, Xu X, Chen G, Pan Y, et al. First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small-cell lung cancer: updated overall survival results from the phase 3 CameL-sq trial. Ann Oncol. 2022;33:S28. doi:https://doi.org/10.1016/j.annonc.2022.02.012.
- Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, et al. Final Overall Survival (OS) Data of Sintilimab Plus Pemetrexed (SPP) and Platinum as First-Line (1L) Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (AMnsqNSCLC) in the phase 3 ORIENT -11 study. Ann Oncol. 2022;33:S28. doi:https://doi.org/10.1016/j.annonc.2022.02.013.
- Hoy SM. Sintilimab: first global approval. Drugs. 2019;79(3):341–346. doi:https://doi.org/10.1007/s40265-019-1066-z.
- Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. doi:https://doi.org/10.1056/NEJMoa1810865.
- Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov KD, et al. LBA51 EMPOWER-Lung 3: cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2021;32:S1328. doi:https://doi.org/10.1016/j.annonc.2021.08.2130.
- Paz-Ares L, Ciuleanu T-E, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198–211. doi:https://doi.org/10.1016/S1470-2045(20)30641-0.
- Johnson M, Cho BC, Luft A, et al. PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as first-line treatment for mNSCLC: results from the phase 3 POSEIDON study. J Thoracic Oncol. 2021;16(10):S844.
- Desai A, Scheckel C, Jensen CJ, Orme J, Williams C, Shah N, et al. Trends in prices of drugs used to treat metastatic non-small cell lung cancer in the US from 2015 to 2020. JAMA Netw Open. 2022;5(1):e2144923. doi:https://doi.org/10.1001/jamanetworkopen.2021.44923.
- Desai A, Sirohi B, Mathew A. Clinical trial access in low- and middle-income countries: a case study on India. Cancer Invest. 2021;39(9):685–689. doi:https://doi.org/10.1080/07357907.2021.1912078.
- Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Trukhin D, et al. 5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON. Ann Oncol. 2022;33:S29–S30. doi:https://doi.org/10.1016/j.annonc.2022.02.014.
- Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017;7(6):596–609. doi:https://doi.org/10.1158/2159-8290.CD-16-1337.
- Zhang Y-L, Yuan J-Q, Wang K-F, Fu X-H, Han X-R, Threapleton D, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985–78993. doi:https://doi.org/10.18632/oncotarget.12587.
- Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101(36):13306–11. doi:https://doi.org/10.1073/pnas.0405220101.
- Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139. doi:https://doi.org/10.1056/NEJMoa040938.
- Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v1–v27. doi:https://doi.org/10.1093/annonc/mdw326.
- Shi YK, Chen G, Wang X, et al. 1O Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: a randomized, double-blind, multi-center, phase III study (FURLONG). Ann Oncol. 2022;33:S27.
- Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. doi:https://doi.org/10.1056/NEJMoa1713137.
- Cross DAE, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046–61. doi:https://doi.org/10.1158/2159-8290.CD-14-0337.
- FDA. FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations 2020. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-adjuvant-therapy-non-small-cell-lung-cancer-egfr-mutations#:∼:text=On%20December%2018%2C%202020%2C%20the,exon%2021%20L858R%20mutations%2C%20as.
- Ballard P, Yates JWT, Yang Z, Kim D-W, Yang JC-H, Cantarini M, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130–5140. doi:https://doi.org/10.1158/1078-0432.CCR-16-0399.
- D’Angelo A, Sobhani N, Chapman R, Bagby S, Bortoletti C, Traversini M, et al. Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): crizotinib, resistance mechanisms and the newer generation of targeted therapies. Cancers. 2020;12(11):3293. doi:https://doi.org/10.3390/cancers12113293.
- FDA. FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer 2016. Available from: https://www.fda.gov/news-events/press-announcements/fda-expands-use-xalkori-treat-rare-form-advanced-non-small-cell-lung-cancer.
- Shaw AT, Riely GJ, Bang Y-J, Kim D-W, Camidge DR, Solomon BJ, et al. Crizotinib in ROS1-rearranged advanced Non-Small-Cell Lung Cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30(7):1121–1126. doi:https://doi.org/10.1093/annonc/mdz131.
- FDA. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC 2019. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc.
- Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, et al. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. J Clin Oncol. 2021;39(11):1253–1263. doi:https://doi.org/10.1200/JCO.20.03025.
- S, Lu, H Pan, L, Wu, Y, Yao, J, He, Y, Wang X, Wang, et al. The efficacy and safety of TQ-B3101 monotherapy in the first line treatment in patients with ROS1 positive non-small cell lung cancer. Ann Oncol. 2022;33:S31. doi:https://doi.org/10.1016/j.annonc.2022.02.017.
- Fang Y, Pan H, Lu S, Hu H, Lu Q. A phase I study to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TQ-B3101. JCO. 2020;38(15_suppl):e21705–e21705. doi:https://doi.org/10.1200/JCO.2020.38.15_suppl.e21705.
- Liang H, Wang M. MET oncogene in non-small cell lung cancer: mechanism of MET dysregulation and agents targeting the HGF/c-Met axis. Onco Targets Ther. 2020;13:2491–2510. doi:https://doi.org/10.2147/OTT.S231257.
- Fujino T, Suda K, Mitsudomi T. Lung cancer with MET exon 14 skipping mutation: genetic feature, current treatments, and future challenges. Lung Cancer. 2021;12:35–50. doi:https://doi.org/10.2147/LCTT.S269307.
- FDA. FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer 2020. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer.
- FDA. FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer.
- Vansteenkiste JF, Van De Kerkhove C, Wauters E, Van Mol P. Capmatinib for the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther. 2019;19(8):659–671. doi:https://doi.org/10.1080/14737140.2019.1643239.
- Wolf J, Seto T, Han J-Y, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944–957. doi:https://doi.org/10.1056/NEJMoa2002787.
- Wolf J, Garon EB, Groen HJM, Tan DSW, Robeva A, Le Mouhaer S, et al. 26P Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced Non-Small Cell Lung Cancer (aNSCLC): updated results from GEOMETRY mono-1. Ann Oncol. 2022;33:S42. doi:https://doi.org/10.1016/j.annonc.2022.02.035.
- EMA. 2022. Available from: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/tabrecta.
- Markham A. Tepotinib: first approval. Drugs. 2020;80(8):829–833. doi:https://doi.org/10.1007/s40265-020-01317-9.
- JCC, Yang M Ahn, H, Sakai M, Morise T, Kato Y, Chen J, Han, et al. 25P – Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping. Ann Oncol. 2022;33 (suppl_2):S41–S70. doi:https://doi.org/10.1016/j.annonc.2022.02.034.
- Markham A. Savolitinib: first approval. Drugs. 2021;81(14):1665–1670. doi:https://doi.org/10.1007/s40265-021-01584-0.
- Lu S, Fang J, Li X, Cao L, Zhou J, Guo Q, et al. Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). JCO. 2020;38(15_suppl):9519–9519. doi:https://doi.org/10.1200/JCO.2020.38.15_suppl.9519.
- S, Lu JF, X, Li L, Cao J, Zhou Q, Guo Z, Liang, et al. 2MO – Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC. Ann Oncol. 2022;33:S27–S70. doi:https://doi.org/10.1016/j.annonc.2022.02.011.